DarioHealth Corp. announced two new contracts to provide integrated chronic condition management solutions for two national employers beginning in the second quarter of 2024. The first employer, a global private investment group, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1. The second employer, a national professional services company, selected Dario's full suite of solutions to deliver personalized support for employees living with cardiometabolic health condition and commonly co-occurring musculoskeletal and behavioral health needs.

Dario combines intelligent technologies with billions of data insights gathered from a decade of consumer engagement to deliver highly personalized experiences that keep members engaged over time for optimal results. Employees enrolled in Dario's cardiomet metabolic solution who are taking a GLP-1 medication will also have access to a tailored experience to support long-term behavior change.